论文部分内容阅读
目的 :探索慢性乙型肝炎 (简称慢乙肝 )的免疫调节治疗。方法 :用乙型肝炎病毒 (HBV)疫苗多次免疫健康的供血员 ,使之产生强的免疫应答 ,然后分离白细胞 ,从中提取转移因子 (暂称“人抗乙肝特异转移因子”或“乙型肝炎高度特异转移因子” ,HSTF)。先后二次进行临床观察 ,治疗组共 2 7例慢乙肝患者用HSTF治疗 ,对照组 1 5例慢乙肝患者用乙肝胎盘肽 (PSTF)治疗。结果 :HBeAg阴转治疗组为 1 4 /2 7例 ,对照组为 2 /1 5例 (P <0 .0 5) ;HBsAg阴转治疗组为 4/2 7例 ,对照组为 0 /1 5例。两次应用HSTF过程中 ,未发现不良反应。结论 :初步的临床研究表明 ,HSTF不仅能改善慢乙肝患者的临床症状 ,还能改善患者体内的乙肝病毒标记物(HBVM) ,其疗效高于PSTF ,能达到与单独应用干扰能 (rIFNα2b)类似的疗效 ;本疗法疗程短 ,费用低 ,未见不良反应。在目前对HBV缺乏特效抗病毒药的情况下 ,HSTF有临床应用价值 ,值得进一步研究
Objective: To explore the immunomodulatory treatment of chronic hepatitis B (chronic hepatitis B). Methods: Hepatitis B virus (HBV) vaccine was used to immunize healthy blood donors repeatedly to produce a strong immune response. Leukocytes were isolated and the transfer factor was extracted from them (tentatively called “human anti-hepatitis B transfer factor” or “type B Hepatitis highly specific transfer factor ”, HSTF). The clinical observation was repeated twice. In the treatment group, 27 patients with chronic hepatitis B were treated with HSTF, while in the control group, 15 patients with chronic hepatitis B were treated with hepatitis B placental peptide (PSTF). Results: The HBeAg negative treatment group was 14/27 in the control group, 2 of 15 cases in the control group (P <0.05), 4/2 of the HBsAg negative control group and 0/1 in the control group 5 cases. HSTF two applications, no adverse reactions were found. Conclusions: Preliminary clinical studies have shown that HSTF not only improves the clinical symptoms of patients with chronic hepatitis B, but also improves hepatitis B virus markers (HBVM) in patients with a higher therapeutic effect than PSTF and is similar to interferon alone (rIFNα2b) The curative effect of this therapy is short, the cost is low, and no adverse reaction is found. In the current lack of effective antiviral drugs for HBV, HSTF has clinical value, it is worth further study